IL6 and osteosarcoma: Our proteomics-based study as well as PRM validation demonstrated that hFXR1p is a prominently increased protein in the rhILG compared with the LG, indicating that hFXR1p may be involved in lobaplatin resistance induced by exogenous IL-6 in osteosarcoma cells.